Literature DB >> 8851465

Recent examples of novel secondary metabolites.

A G Brown1.   

Abstract

Modern trends in the detection, isolation and characterization of leads for novel therapeutic compounds are reviewed. Some current biological test systems (immunological, chemical, enzymic, receptor, etc.) and examples of their successful application are highlighted including the structures of selected novel and prospective metabolites.

Mesh：

Substances：

Year:  1995        PMID： 8851465     DOI： 10.1007/bf02816526

Source DB:  PubMed          Journal:  Folia Microbiol (Praha)        ISSN： 0015-5632            Impact factor:   2.099


  29 in total

1.  ML-236A, ML-236B, and ML-236C, new inhibitors of cholesterogenesis produced by Penicillium citrinium.

Authors:  A Endo; M Kuroda; Y Tsujita
Journal:  J Antibiot (Tokyo)       Date:  1976-12       Impact factor: 2.649

2.  New paraherquamide antibiotics with anthelmintic activity.

Authors:  S E Blanchflower; R M Banks; J R Everett; B R Manger; C Reading
Journal:  J Antibiot (Tokyo)       Date:  1991-05       Impact factor: 2.649

3.  Crystal and molecular structure of compactin, a new antifungal metabolite from Penicillium brevicompactum.

Authors:  A G Brown; T C Smale; T J King; R Hasenkamp; R H Thompson
Journal:  J Chem Soc Perkin 1       Date:  1976

Review 4.  Avermectins and milbemycins.

Authors:  H G Davies; R H Green
Journal:  Nat Prod Rep       Date:  1986-04       Impact factor: 13.423

5.  Cyclophostin, acetylcholinesterase inhibitor from Streptomyces lavendulae.

Authors:  T Kurokawa; K Suzuki; T Hayaoka; T Nakagawa; T Izawa; M Kobayashi; N Harada
Journal:  J Antibiot (Tokyo)       Date:  1993-08       Impact factor: 2.649

Review 6.  Applications of combinatorial technologies to drug discovery. 1. Background and peptide combinatorial libraries.

Authors:  M A Gallop; R W Barrett; W J Dower; S P Fodor; E M Gordon
Journal:  J Med Chem       Date:  1994-04-29       Impact factor: 7.446

Review 7.  Screening microbial metabolites for new drugs--theoretical and practical issues.

Authors:  G G Yarbrough; D P Taylor; R T Rowlands; M S Crawford; L L Lasure
Journal:  J Antibiot (Tokyo)       Date:  1993-04       Impact factor: 2.649

8.  Phthoxazolin A, a specific inhibitor of cellulose biosynthesis from microbial origin. I. Discovery, taxonomy of producing microorganism, fermentation, and biological activity.

Authors:  Y Tanaka; I Kanaya; Y Takahashi; M Shinose; H Tanaka; S Omura
Journal:  J Antibiot (Tokyo)       Date:  1993-08       Impact factor: 2.649

9.  Metabolic products of microorganisms. 261. Obscurolides, a novel class of phosphodiesterase inhibitors from streptomyces. I. Production, isolation, structural elucidation and biological activity of obscurolides A1 to A4.

Authors:  H Hoff; H Drautz; H P Fiedler; H Zähner; J E Schultz; W Keller-Schierlein; S Philipps; M Ritzau; A Zeeck
Journal:  J Antibiot (Tokyo)       Date:  1992-07       Impact factor: 2.649

10.  Quinolidomicins A1, A2 and B1, novel 60-membered macrolide antibiotics. I. Taxonomy, fermentation, isolation, physico-chemical properties and biological activity.

Authors:  Y Hayakawa; M Matsuoka; K Shin-ya; H Seto
Journal:  J Antibiot (Tokyo)       Date:  1993-10       Impact factor: 2.649
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.